Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Norgine
Norgine House
Widewater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS UK
Tel: +44 (0) 1895 826 600
Norgine is a specialty pharmaceutical company with an extensive and balanced pan-European presence. Above and beyond Europe, its products are sold in a total of 53 countries worldwide. Its areas of expertise are principally in gastroenterology, hepatology and incontinence.
Founded in 1906 by Dr Victor Stein, Norgine is still privately owned and Peter Stein, a grand-nephew of the founder, is now Chairman and CEO. The company’s core focus is on gastroenterology and hepatology. Norgine develops and manufactures innovative pharmaceutical products, which are then marketed through their own subsidiaries and in collaboration with a network of partners around the world.
Norgine’s total revenue in 2009 was €257 million. In 2009 product sales increased to €253 million, the 23rd consecutive year of double-digit growth at constant exchange rates. MOVICOL is Norgine’s number one product and accounts for over 50% of total sales.
Norgine currently has a strong product development pipeline including a number of projects entering advanced clinical studies.
The company has a manufacturing facility in the UK, but no R&D.
Movicol
Moviprep
Klean-Prep
Oramorph
Normacol
Pyralvex
Spasmonal
Fivasa
Nortussine
Xifaxan
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
